Hydroxychloroquine treatment for COVID19 rejected by giants of the global health establishment
The World Health Organisation (WHO) has removed the drug hydroxychloroquine from its Solidarity trial, in which possible treatments for Covid-19 are being tested.
The latest development is yet another twist in the extraordinary tale of an inexpensive drug that has been used for decades to treat rheumatoid arthritis and is also given to patients with malaria and lupus.
In the case of Covid-19, the use of hydroxychloroquine as a treatment or a prophylactic has been the subject of huge controversy and the drug has now been rejected by the behemoths of the global health establishment, the WHO and the Food and Drug Administration (FDA) in the United States.
The US president, Donald Trump, even entered the fray over hydroxychloroquine, saying that he had been taking it as a prophylactic.
In what has become known as Lancetgate, a major article about hydroxychloroquine that influenced global policy has been retracted.
